<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034900</url>
  </required_header>
  <id_info>
    <org_study_id>bakircaymzeren05</org_study_id>
    <nct_id>NCT05034900</nct_id>
  </id_info>
  <brief_title>Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis?</brief_title>
  <official_title>Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izmir Bakircay University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Izmir Bakircay University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oscillatory positive expiratory pressure (OPEP) devices such as Flutter®, Aerobika® or Shaker&#xD;
      ® are commonly prescribed in the clinical practice for airway clearance in children with&#xD;
      chronic lung diseases including bronchiectasis, cystic fibrosis, and primary ciliary&#xD;
      dyskinesia. Health insurance companies may cover these devices in some countries; but this is&#xD;
      not a common practice around the world. Therefore, many families have to purchase these&#xD;
      devices themselves. Unfortunately, these devices are rather expensive especially in the&#xD;
      developing countries and consequently, families become financially burdened. Aim of this&#xD;
      study is to investigate whether the addition of OPEP devices to a comprehensive chest&#xD;
      physiotherapy program provide additional benefits on pulmonary function and exercise capacity&#xD;
      in children with bronchiectasis. Results of this study may help better interpreting the&#xD;
      cost-effectiveness of these devices.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Forced Vital Capacity (FVC) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Forced Vital Capacity (FVC) will be measured using Spiropalm 6MWT device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Forced Expiratory Volume in 1 second (FEV1) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) will be measured using Spiropalm 6MWT device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Peak Expiratory Flow (PEF) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Peak Expiratory Flow (PEF) will be measured using Spiropalm 6MWT device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline maximum minute ventilation at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Maximum minute ventilation will be measured using Spiropalm 6MWT device during six-minute walk test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline breathing reserve at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Breathing reserve will be measured using Spiropalm 6MWT device during six-minute walk test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline six-minute walk distance at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Distance walked in six minutes will be recorded in six-minute walk test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline M. Quadriceps strength at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>M. Quadriceps strength will be measured using hand-held dynamometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Leicester Cough Questionnaire score at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Questionnaire consists of 19 items covering physical, psychological and social domains of chronic cough with a 7 point likert response scale (range from 1 to 7). Higher score indicates better quality of life.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Chest Physiotherapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will perform comprehensive chest physiotherapy program two times a day, 7 days a week for 8 weeks at their homes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPEP device + Chest Physiotherapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the same physiotherapy program applied to the controls, patients in this group will also use OPEP device two times a day, 7 days a week for 8 weeks at their homes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chest physiotherapy</intervention_name>
    <description>Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.</description>
    <arm_group_label>Chest Physiotherapy Group</arm_group_label>
    <arm_group_label>OPEP device + Chest Physiotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oscillatory Positive Expiratory Pressure (OPEP) device</intervention_name>
    <description>Shaker® device will be used.</description>
    <arm_group_label>OPEP device + Chest Physiotherapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of bronchiectasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalization history during past month&#xD;
&#xD;
          -  Diagnosis of any other chronic childhood diseases such as cerebral palsy or&#xD;
             neuromuscular diseases which may impede exercise tolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melih Zeren, PhD, PT</last_name>
    <phone>+90 536 877 28 62</phone>
    <email>fzt.zeren@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meral Barlık, MD</last_name>
    <phone>+90 505 257 12 85</phone>
    <email>meralozfindik@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ege University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Pulmonology</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meral Barlık, MD</last_name>
      <phone>+90 505 257 12 85</phone>
      <email>meralozfindik@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Izmir Bakircay University</investigator_affiliation>
    <investigator_full_name>Melih Zeren</investigator_full_name>
    <investigator_title>Assist. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>bronchiectasis</keyword>
  <keyword>children</keyword>
  <keyword>oscillatory positive expiratory pressure device</keyword>
  <keyword>chest physiotherapy</keyword>
  <keyword>pulmonary function</keyword>
  <keyword>exercise capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

